Invivo Anti-Mouse ICOS Recombinant mAb
Invivo Anti-Mouse ICOS Recombinant mAb
Product Details
Product Details
Product Specification
| Host | Rat |
| Antigen | ICOS |
| Synonyms | Inducible T-cell costimulator; Activation-inducible lymphocyte immunomediatory molecule; CD28 and CTLA-4-like protein (CCLP); CD28-related protein 1 (CRP-1); CD278; Ailim; Icos |
| Location | Cell membrane |
| Accession | Q9WVS0 |
| Clone Number | S-3778 |
| Antibody Type | Rat mAb |
| Isotype | Rat IgG2b,k |
| Application | FCM, in vivo blocking of ICOS/ICOSL signaling |
| Purification | Protein G |
| Concentration | 5 mg/ml |
| Purity | >95%(Determined by SDS-PAGE) |
| Endotoxin | <1EU/mg |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage | 2 to 8 °C for 2 weeks under sterile conditions; |
Background
ICOS (inducible T-cell costimulator, CD278) is a 55–60 kDa disulfide-linked homodimeric CD28-superfamily receptor expressed mainly on activated CD4⁺ and CD8⁺ T cells, Th17, Tfh and some NK subsets; its surface engagement by the ligand ICOSL (B7-H2/CD275) on antigen-presenting cells delivers a critical secondary signal that amplifies PI3K–AKT–mTOR and MAPK cascades, enhances cytokine transcription (IL-4, IL-10, IL-17, IL-21, IFN-γ), stabilizes Tfh differentiation, germinal-center reactions and class-switch recombination, and promotes memory formation, whereas genetic loss or therapeutic blockade of ICOS attenuates autoimmune pathology in experimental allergic encephalomyelitis, lupus, colitis and graft-versus-host disease yet can dampen antitumor immunity, making the pathway a finely balanced target for both immunosuppressive and immunostimulatory clinical interventions.
